目的 建立鹽酸罌粟堿注射液合理性評價標準，評價鹽酸罌粟堿注射液臨床使用合理性。方法 以鹽酸罌粟堿注射液說明書、國內(nèi)外指南及專家共識為基礎(chǔ)制定合理性評價標準，對亳州市人民醫(yī)院2023年1～12月260例患者使用鹽酸罌粟堿注射液的出院病歷進行評價。結(jié)果 260例病歷中，合理（C_i≥0.8）84例（32.31%），基本合理（0.6≤C_i＜0.8）67例（25.77%），不合理（C_i＜0.6）病歷109例（41.92%）。主要不合理問題表現(xiàn)為無適應(yīng)證用藥73例（28.08%）、用法用量不適宜86例（33.08%）、使用療程過長31例（11.92%）、溶媒選擇不適宜9例（3.46%）和藥物相互作用129例（49.62%）等。結(jié)論 基于加權(quán)TOPSIS法評價鹽酸罌粟堿注射液是切實可行的，結(jié)果表明亳州市人民醫(yī)院存在一些不合理使用現(xiàn)象，醫(yī)院應(yīng)加強不合理用藥管理力度，確保臨床合理用藥。

Objective To establish the rationality evaluation criteria of Papaverine Hydrochloride Injection, and evaluate the rationality of the clinical use of Papaverine Hydrochloride Injection. Methods Based on the instructions for Papaverine Hydrochloride Injection, domestic and international guidelines, and expert consensus, the rationality evaluation standard was developed to evaluate the discharge medical records of 260 patients using Papaverine Hydrochloride Injection in Bozhou People’s Hospital from January to December 2023. Results Among the 260 medical records, 84 cases (32.31%) were reasonable (C_i≥0.8), 67 cases (25.77%) were basically reasonable (0.6≤C_i＜0.8), and 109 cases (41.92%) were unreasonable (C_i＜0.6). The main unreasonable problems were manifested in 73 cases (28.08%) of medication without indication, 86 cases (33.08%) of inappropriate dosage, 31 cases (11.92%) of excessive use of treatment course, 9 cases (3.46%) of inappropriate choice of solvent, and 129 cases (49.62%) of drug interactions. Conclusion It is feasible to evaluate Papaverine Hydrochloride Injection based on the weighted TOPSIS method, and the results indicate that there are more unreasonable uses in Bozhou People’s Hospital. The hospital should strengthen the management of unreasonable use of drugs to ensure rational use in clinic.

R972

亳州市衛(wèi)生健康科研重點項目（bzwj2022a002）